Healthcare
Oculis Holding AG(OCS)
Live Price
Offline$11.22
-0.71% today
1Y Change
-40.53%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $1.23B
- Revenue Growth
- -100.0%
- EPS Growth
- +14.6%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Oculis Holding AG (OCS) is a Healthcare stock with a market cap of $1.23B and listed on NASDAQ. The stock last traded around $11.22 and down 40.5% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +14.6%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +14.6%, free cash flow -31.0% with operating margin -16254.4% and ROIC -40.9%. Valuation already assumes a fairly strong business story at price/sales 2437.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines OCS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
-16254.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at +14.6%, with operating margin around -16254.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +5.0% | -2.8% | -63.9% |
2026 Mar 3, 2026 | -6.7% | +0.5% | +3.9% | -3.6% |
2025 Nov 10, 2025 | +20.0% | -0.1% | -1.4% | +5.7% |
Benchmark Edge
OCS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OCS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OCS Max Drawdown
-67.20%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OCS and SPY.
Company Overview
Oculis Holding AG
NASDAQ Global Market
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
- Leadership
- Riad Sherif
- IPO Date
- May 18, 2021
- Employees
- 49
- Street Address
- Bahnhofstrasse 7
- Mailing
- Zug, 6300
- Region
- Zug, CH
- Reporting Currency
- USD
- Investor Line
- 41 58 810 0182
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2437.5
- Price/Book
- 6.1
Growth
- Revenue
- -100.0%
- EPS
- +14.6%
- Free Cash Flow
- -31.0%
Profitability
- Gross Margin
- -2858.1%
- Operating Margin
- -16254.4%
- Net Margin
- -19598.9%
- ROE
- -62.5%
- ROIC
- -40.9%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 5.96
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.